Eleva is a clinical-stage biopharmaceutical company that strives to bring novel therapies to patients in need. Partnerships are at the heart of our strategy. Our unique moss-based platform and capabilities can unlock a range of 1^st- and best-in-class biologics.

We are currently advancing two proprietary clinical programs, which have the potential to change the life of patients affected from complement-related disorders (e.g. C3G, dry AMD) and Fabry disease. Eleva is currently looking for additional investors and partners to accelerate the development of these clinical assets towards market approval.

Moreover, Eleva scouts for promising novel compounds that will benefit from Eleva’s technology and expertise. We are evaluating alliances to initiate partnered discovery and development projects.

Eleva has the following two assets in clinical development:

Eleva is advancing its proprietary, moss-expressed Factor H (CPV-104) program into clinical development (CTA filing achieved in Q4/2024) with an initial focus on C3 Glomerulopathy (C3G). Our compound has the potential to restore the natural balance in the complement system, thereby controlling over-activation while retaining its protective properties. Beyond C3G, the program has shown therapeutic potential in a range of indications including atypical hemolytic uremic syndrome (aHUS) and the dry form of age-related macular degeneration (dry AMD).  

Eleva’s glyco-improved form of alpha Galactosidase - aGal (RPV-001) expressed in moss, has shown promising effects in a clinical Phase1b trial. Eleva’s proprietary aGal (RPV-001) exhibits superior cell uptake, prolonged efficacy and improved long-term safety. The recombinant aGal (RPV-001) program is a prime example for the positive impact of our proprietary expression system on key product capabilities otherwise unattainable with conventional production cell lines.

Our assets obtain their superior properties from our moss-based technology platform, which is built around a highly robust 3D fermentation process.

Eleva continues to scout for promising compounds beyond its current pipeline and is open for alliances to initiate partnered discovery and development projects. Our recent alliance with 3PBIOVIAN, a leading CDMO, has secured GMP production capacity to support the clinical development our current and future pipeline projects. If you want to unlock the full potential of your complex highly glycosylated biologic, we would appreciate meeting at BIO International.